Amblyopia treatment strategies and new drug therapies

Journal of Pediatric Ophthalmology and Strabismus

Volumn 51, Issue 2, 2014, Pages 78-86

  Pescosolido, Nicola ^a   Stefanucci, Alessio ^a   Buomprisco, Giuseppe ^a   Fazio, Stefano ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BICUCULLINE; CARBIDOPA PLUS LEVODOPA; CITICOLINE; PHENETHYLAMINE;

AMBLYOPIA; ANISOMETROPIA; CATARACT; CONGENITAL CATARACT; DISEASE ASSOCIATION; HUMAN; MONOCULAR VISION; NERVE CELL PLASTICITY; PTOSIS; REVIEW; STRABISMUS; VISUAL ACUITY; VISUAL DEPRIVATION; VISUAL IMPAIRMENT;

ADULT; AMBLYOPIA; BANDAGES; BICUCULLINE; CARBIDOPA; CHILD; CHILD, PRESCHOOL; CYTIDINE DIPHOSPHATE CHOLINE; DOPAMINE AGONISTS; DRUG COMBINATIONS; GABA-A RECEPTOR ANTAGONISTS; HUMANS; LEVODOPA; NEURONAL PLASTICITY; NOOTROPIC AGENTS; OPHTHALMIC SOLUTIONS; PHENETHYLAMINES; REFRACTIVE ERRORS; SENSORY DEPRIVATION; STRABISMUS; TRANSCRANIAL MAGNETIC STIMULATION; VISUAL CORTEX;

EID: 84898805926     PISSN: 01913913     EISSN: 19382405     Source Type: Journal    
DOI: 10.3928/01913913-20130107-01     Document Type: Review

References (138)

1. Wong AM. New concepts concerning the neural mechanisms of amblyopia and their clinical implications. Can J Ophthalmol. 2012;47:399-409.
2. Buch H, Vinding T, La Cour M, Nielsen NV. The prevalence and causes of bilateral and unilateral blindness in an elderly urban Danish population: the Copenhagen City Eye Study. Acta Ophthalmol Scand. 2001;79:441-449.
3. Brown SA, Weih LM, Fu CL, Dimitrov P, Taylor HR, McCarty CA. Prevalence of amblyopia and associated refractive errors in an adult population in Victoria, Australia. Ophthalmic Epidemiol. 2000;7:249-258.
4. Polling JR, Loudon SE, Klaver CC. Prevalence of amblyopia and refractive errors in an unscreened population of children. Optom Vis Sci. 2012;89:e44-e49.
5. Attebo K, Mitchell P, Cumming R, Smith W, Jolly N, Sparkes R. Prevalence and causes of amblyopia in an adult population. Ophthalmology. 1998;105:154-159.
6. Thompson JR, Woodruff G, Hiscox FA, Strong N, Minshull C. The incidence and prevalence of amblyopia detected in childhood. Public Health. 1991;105:455-462.
7. Harauzov A, Spolidoro M, DiCristo G, et al. Reducing intracortical inhibition in the adult visual cortex promotes ocular dominance plasticity. J Neurosci. 2010;30:361-371.
8. Maya Vetencourt JF, Sale A, Viegi A, et al. The antidepressant fluoxetine restores plasticity in the adult visual cortex. Science. 2008;320:385-388.
9. Putignano E, Lonetti G, Cancedda L, et al. Developmental downregulation of histone posttranslational modifications regulates visual cortical plasticity. Neuron. 2007;53:747-759.
10. Silingardi D, Scali M, Belluomini G, Pizzorusso T. Epigenetic treatments of adult rats promote recovery from visual acuity deficits induced by long-term monocular deprivation. Eur J Neurosci. 2010;31:2185-2192.
11. McKee SP, Levi DM, Movshon JA. The pattern of visual deficits in amblyopia. J Vis. 2003;3:380-405.
12. Loudon SE, Polling JR, Simonsz HJ. Electronically measured compliance with occlusion therapy for amblyopia is related to visual acuity increase. Graefes Arch Clin Exp Ophthalmol. 2003;241:176-180.
13. Friedman DS, Repka MX, Katz J, et al. Prevalence of amblyopia and strabismus in white and African-American children aged 6 through 71 months: the Baltimore Pediatric Eye Disease Study. Ophthalmology. 2009;116:2128-2134.
14. Pediatric Eye Disease Investigator Group. The clinical profile of moderate amblyopia in children younger than 7 years. Arch Ophthalmol. 2002;120:281-287.
15. von Noorden GK, Crawford ML. The lateral geniculate nucleus in human strabismic amblyopia. Invest Ophthalmol Vis Sci. 1992;33:2729-2732.
16. Wiesel TN, Hubel DH. Single-cell responses in striate cortex of kittens deprived of vision in one eye. J Neurophysiol. 1963;26:1003-1017.
17. Wiesel TN, Hubel DH. Comparison of the effects of unilateral and bilateral eye closure on cortical unit responses in kittens. J Neurophysiol. 1965;28:1029-1040.
18. Wiesel TN. Postnatal development of the visual cortex and the influence of environment. Nature. 1982;299:583-591.
19. Tychsen L, Burkhalter A. Nasotemporal asymmetries in area V1: ocular dominance columns of infant, adult, and strabismic macaque monkeys. J Comp Neurol. 1997;388:32-46.
20. Kiorpes L, Mckee SP. Neural mechanisms underlying amblyopia. Curr Opin Neurobiol. 1999;9:480-486.
21. Sengpiel F. Experimental models of amblyopia: insights for prevention and treatment. Strabismus. 2011;19:87-90.
22. Mitchell DE, Sengpiel F, Hamilton DC, Schwarzkopf DS, Kennie J. Protection against deprivation amblyopia depends on relative not absolute daily binocular exposure. J Vis. 2011;11:13.
23. Mitchell DE, Kennie J, Schwarzkopf DS, Sengpiel F. Daily mixed visual experience that prevents amblyopia in cats does not always allow the development of good binocular depth perception. J Vis. 2009;9:221-227.
24. Li C, Cheng L, Yu Q, Xie B, Wang J. Relationship of visual cortex function and visual acuity in anisometropic amblyopic children. Int J Med Sci. 2012;9:115-120.
25. Rislove EM, Hall EC, Stavros KA, Kiorpes L. Scale-dependent loss of global form perception in strabismic amblyopia. J Vis. 2010;10:25.
26. Dallala R, Wang YZ, Hess RF. The global shape detection deficit in strabismic amblyopia: contribution of local orientation and position. Vision Res. 2010;50:1612-1617.
27. Levi DM, Yu C, Kuai SG, Rislove E. Global contour processing in amblyopia. Vision Res. 2007;47:512-524.
28. Levi DM. Crowding: an essential bottleneck for object recognition: a mini-review. Vision Res. 2008;48:635-654.
29. Hou C, Good WV, Norcia AM. Validation study of VEP vernier acuity in normal-vision and amblyopic adults. Invest Ophtalmol Vis Sci. 2007;48:4070-4078.
30. Simmers AJ, Bex PJ. The representation of global spatial structure in amblyopia. Vision Res. 2004;44:523-533.
31. Mansouri B, Allen HA, Hess RF. Detection, discrimination and integration of second-order orientation information in strabismic and anisometropic amblyopia. Vision Res. 2005;45:2449-2460.
32. Hess RF, Howell ER. The threshold contrast sensitivity function in strabismic amblyopia: evidence for a two type classification. Vision Res. 1977;17:1049-1055.
33. Hayward J, Truong G, Partanen M, Giaschi D. Effects of speed, age, and amblyopia on the perception of motion-defined form. Vision Res. 2011;15;51:2216-2223.
34. Mirabella G, Hay S, Wong AM. Deficits in perception of images of real-world scenes in patients with a history of amblyopia. Arch Ophthalmol. 2011;129:176-183.
35. Grant S, Moseley MJ. Amblyopia and real-world visuomotor tasks. Strabismus. 2011;19:119-128.
36. Webber AL, Wood JM, Gole GA, Brown B. The effect of amblyopia on fine motor skills in children. Invest Ophthalmol Vis Sci. 2008;49:594-603.
37. Niechwiej-Szwedo E, Goltz HC, Chandrakumar M, Hirji ZA, Wong AM. Effects of anisometropic amblyopia on visuomotor behavior, I: saccadic eye movements. Invest Ophthalmol Vis Sci. 2010;51:6348-6354.
38. Niechwiej-Szwedo E, Goltz HC, Chandrakumar M, Hirji Z, Crawford JD, Wong AM. Effects of anisometropic amblyopia on visuomotor behavior: Part 2. Visually guided reaching. Invest Ophthalmol Vis Sci. 2011;52:795-803.
39. Demer JL, von Noorden GK, Volkow ND, Gould KL. Imaging of cerebral blood flow and metabolism in amblyopia by positron emission tomography. Am J Ophthalmol. 1988;105:337-347.
40. Choi MY, Lee DS, Hwang JM, et al. Characteristics of glucose metabolism in the visual cortex of amblyopes using positronemission tomography and statistical parametric mapping. J Pediatr Ophthalmol Strabismus. 2002;39:11-19.
41. Lv B, He H, Li X, et al. Structural and functional deficits in human amblyopia. Neurosci Lett. 2008;437:5-9.
42. Goodyear BG, Nicolle DA, Humphrey GK, Menon RS. BOLD fMRI response of early visual areas to perceived contrast in human amblyopia. J Neurophysiol. 2000;84:1907-1913.
43. Choi MY, Lee KM, Hwang JM, et al. Comparison between anisometropic and strabismic amblyopia using functional magnetic resonance imaging. Br J Ophthalmol. 2001;85:1052-1056.
44. Anderson SJ, Swettenham JB. Neuroimaging in human amblyopia. Strabismus. 2006;14:21-35.
45. Lerner Y, Pianka P, Azmon B, et al. Area-specific amblyopic effects in human occipitotemporal object representations. Neuron. 2003;40:1023-1029.
46. Muckli L, Kiess S, Tonhausen N, Singer W, Goebel R, Sireteanu R. Cerebral correlates of impaired grating perception in individual, psychophysically assessed human amblyopes. Vision Res. 2006;46:506-526.
47. Secen J, Culham J, Ho C, Giaschi D. Neural correlates of the multiple-object tracking deficit in amblyopia. Vision Res. 2011;51:2517-2527.
48. Berardi N, Pizzorusso T, Maffei L. Critical periods during sensory development. Curr Opin Neurobiol. 2000;10:138-145.
49. Li RW, Ngo C, Nguyen J, Levi DM. Video-game play induces plasticity in the visual system of adults with amblyopia. PLoS Biol. 2011;9:e1001135.
50. Medghalchi AR, Dalili S. A randomized trial of atropine vs patching for treatment of moderate amblyopia. Iran Red Crescent Med J. 2011;13:578-581.
51. Longmuir S, Pfeifer W, Scott W, Olson R. Effect of occlusion amblyopia after prescribed full-time occlusion on long-term visual acuity Outcomes. J Pediatr Ophthalmol Strabismus. 2012;4:1-8.
52. Baroncelli L, Maffei L, Sale A. New perspectives in amblyopia therapy on adults: a critical role for the excitatory/inhibitory balance. Front Cell Neurosci. 2011;5:25.
53. Webber AL, Wood J. Amblyopia: prevalence, natural history, functional effects and treatment. Clin Experiment Optom. 2005;88:365-375.
54. Lam GC, Repka MX, Guyton DL. Timing of amblyopia therapy relative to strabismus surgery. Ophthalmology. 1993;100:1751-1756.
55. Moseley MJ, Neufeld M, McCarry B, et al. Remediation of refractive amblyopia by optical correction alone. Ophthalmic Physiol Opt. 2002;22:296-299.
56. Repka MX, Beck RW, Holmes JM, et al. A randomized trial of patching regimens for treatment of moderate amblyopia in children. Arch Ophthalmol. 2003;121:603-611.
57. Patil PA, Meenakshi S, Surendran TS. Refractory reverse amblyopia with atropine penalization. Oman J Ophthalmol. 2010;3:148-149.
58. Repka MX, Kraker RT, Beck RW, et al. Treatment of severe amblyopia with atropine: results from 2 randomized clinical trials. J AAPOS. 2009;13:529.
59. Campbell FW, Hess RF, Watson PG, Banks R. Preliminary results of a physiologically based treatment of amblyopia. Br J Ophthalmol. 1978;62:748-755.
60. Tytla ME, Labow-Daily LS. Evaluation of the CAM treatment for amblyopia: a controlled study. Invest Ophthalmol Vis Sci. 1981;20:400-406.
61. Nyman KG, Singh G, Rydberg A, Fornander M. Controlled study comparing CAM treatment with occlusion therapy. Br J Ophthalmol. 1983;67:178-180.
62. Huang CB, Zhou Y, Lu ZL. Broad bandwidth of perceptual learning in the visual system of adults with anisometropic amblyopia. Proc Natl Acad Sci USA. 2008;105:4068-4073.
63. Hussain Z, Webb BS, Astle AT, McGraw PV. Perceptual learning reduces crowding in amblyopia and in the normal periphery. J Neurosci. 2012;32:474-480.
64. Suttle CM. Active treatments for amblyopia: a review of the methods and evidence base. Clin Exp Optom. 2010;93:287-299.
65. Polat U, Ma-Naim T, Spierer A. Treatment of children with amblyopia by perceptual learning. Vision Res. 2009;49:2599-2603.
66. Hussain Z, Webb BS, Astle AT, McGraw PV. Perceptual learning reduces crowding in amblyopia and in the normal periphery. J Neurosci. 2012;32:474-480.
67. Polat U, Ma-Naim T, Belkin M, Sagi D. Improving vision in adult amblyopia by perceptual learning. Proc Natl Acad Sci USA. 2004;101:6692-6697.
68. Chen PL, Chen JT, Fu JJ, Chien KH, Lu DW. A pilot study of anisometropic amblyopia improved in adults and children by perceptual learning: an alternative treatment to patching. Ophthalmic Physiol Opt. 2008;28:422-428.
69. Barker AT, Jalinous R, Freeston IL. Non-invasive magnetic stimulation of human motor cortex. Lancet. 1985;1:1106-1107.
70. Hallet M. Transcranial magnetic stimulation: a primer. Neuron. 2007;55:187-199.
71. George MS. Transcranial magnetic stimulation for the treatment of depression. Expert Rev Neurother. 2010;10:1761-1772.
72. Hummel FC, Cohen LG. Non-invasive brain stimulation: a new strategy to improve neurorehabilitation after stroke? Lancet Neurol. 2006;5:708-712.
73. Thompson B, Mansouri B, Koski L, Hess RF. Brain plasticity in the adult: modulation of function in amblyopia with rTMS. Curr Biol. 2008;18:1067-1071.
74. Hess RF, Thompson B. New insights into amblyopia: binocular therapy and non invasive brain stimulation. J AAPOS. 2013;17:89-93.
75. Waddingham PE, Butler TK, Cobb SV, et al. Preliminary results from the use of the novel Interactive Binocular Treatment (I-BiT) system, in the treatment of strabismic and anisometropic amblyopia. Eye (Lond). 2006;20:375-378.
76. Eastgate RM, Griffiths GD, Waddingham PE, et al. Modified virtual reality technology for treatment of amblyopia. Eye (Lond). 2006;20:370-374.
77. Mansouri B, Thompson B, Hess RF. Measurement of suprathreshold binocular interactions in amblyopia. Vision Res. 2008;48:2775-2784.
78. Hess RF, Mansouri B, Thompson B. A new binocular approach to the treatment of amblyopia in adults well beyond the critical period of visual development. Restor Neurol Neurosci. 2010;28:1-10.
79. Hess RF, Mansouri B, Thompson B. A binocular approach to treating amblyopia: anti-suppression therapy. Optom Vis Sci. 2010;87:697-704.
80. Leguire LE, Walson PD, Rogers GL, Bremer DL, McGregor ML. Longitudinal study of levodopa/carbidopa for childhood amblyopia. J Pediatr Ophthalmol Strabismus. 1993;30:354-360.
81. Yeh KC, August TF, Busch DF, et al. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. Neurology. 1989;39:25-38.
82. Sinemet [package insert]. Whitehouse Station, NJ: Merck Co., Inc.; 2005.
83. Gordon N. Segawa's disease: dopa-responsive dystonia. Int J Clin Pract. 2008;62:943-946.
84. Procianoy E, Fuchs FD, Procianoy L, Procianoy F. The effect of increasing doses of levodopa on children with strabismic amblyopia. J AAPOS. 1999;3:337-340.
85. Mohan K, Dhankar V, Sharma A. Visual acuities after levodopa administration in amblyopia. J Pediatr Opthalmol Strabismus. 2001;38:62-67.
86. Dadeya S, Vats P, Malikk KP. Levodopa/carbidopa in the treatment of amblyopia. J Pediatr Ophthalmol Strabismus. 2009;46:87-90.
87. Procianoy E, Fuchs FD, Procianoy L, Procianoy F. The effect of increasing doses of levodopa on children with strabismic amblyopia. J AAPOS. 1999;3:337-340.
88. Leguire LE, Rogers GL, Bremer DL, Walson PD, Hadjiconstantinou-Neff M. Levodopa and childhood amblyopia. J Pediatr Ophthalmol Strabismus. 1992;29:290-298.
89. Leguire LE, Komaromy KL, Nairus TM, Rogers GL. Long-term follow up of L-dopa treatment in children with amblyopia. J Pediatr Ophthalmol Strabismus. 2002;39:326-330.
90. Leguire LE, Walson PD, Rogers GL, Bremer DL, McGregor ML. Longitudinal study of levodopa/carbidopa for childhood amblyopia. J Pediatr Opthalmol Strabismus. 1993;30:354-360.
91. Gottlob I, Wizov SS, Reinecke RD. Visual acuities and scotomas after 3 weeks' levodopa administration in adult amblyopia. Graefes Arch Clin Exp Ophthalmol. 1995;233:407-413.
92. Bhartiya P, Sharma P, Biswas NR, Tandon R, Khokhar SK. Levodopa-carbidopa with occlusion in older children with amblyopia. J AAPOS. 2002;6:368-372.
93. Yang X, Luo D, Liao M, Chen B, Liu L. Efficacy and tolerance of levodopa to treat amblyopia: a systematic review and metaanalysis. [published online ahead of print May 29, 2013]. Eur J Ophthalmol. doi: 10.5301/ejo.5000174
94. Rashad MA. Pharmacological enhancement of treatment for amblyopia. Clin Ophthalmol. 2012;6:409-416.
95. Nguyen-Lergos J, Durand J, Simon A. Catecholamine cell types in the human retina. Clin Vis Sci. 1992;7:435-447.
96. Archibald NK, Clarke MP, Mosimann UP, Burn DJ. The retina in Parkinson's disease. Brain. 2009;132:1128-1145.
97. Witkovsky P. Dopamine and retinal function. Doc Ophthalmol. 2004;108:17-40.
98. Huemer KH, Garhofer G, Zawinka C, et al. Effects of dopamine on human retinal vessel diameter and its modulation during flicker stimulation. Am J Physiol Heart Circ Physiol. 2003;284:H358-H363.
99. Huemer KH, Zawinka C, Garhöfer G, et al. Effects of dopamine on retinal and choroidal blood flow parameters in humans. Br J Ophthalmol. 2007;91:1194-1198.
100. Von Noorden GK, Crawford ML. The lateral geniculate nucleus in human strabismic amblyopia. Invest Ophthalmol Vis Sci. 1992;33:2729-2732.
101. Sireteanu R, Tonhousen N, Muckli L. Cortical site of amblyopic deficit in anisometropic and strabismic subjects investigated with MRI. Invest Ophthalmol Vis Sci. 1998;39(suppl):S909.
102. Sun XN, Zhang JS. Influences of levodopa on expression of Nmethyl-D-aspartate receptor-1-subunit in the visual cortex of monocular deprivation rats. Int J Ophthalmol. 2012;5:50-54.
103. Feng LX, Zhao KX. Study on anisometropic amblyopia by simultaneously recording multifocal VEP and multifocal ERG [article in Chinese]. Zhonghua Yan Ke Za Zhi. 2005;41:41-46.
104. Burguera JA, Vilela C, Traba A, Ameave Y, Vallet M. The electroretinogram and visual evoked potentials in patients with Parkinson's disease [article in Spanish]. Arch Neurobiol. 1990;53:1-7.
105. Bodis-Wollner I. Visual electrophysiology in Parkinson's disease: PERG, VEP and visual P300. Clin Electroencephalogr. 1997;28:143-147.
106. Gottlob I, Weghaupt H, Vass C. Effect of levodopa on the human luminance electroretinogram. Invest Ophthalmol Vis Sci. 1990;31:1252-1258.
107. Bartel P, Blom M, Robinson E, van der Meyden C, Sommers DK, Becker P. The effects of levodopa and haloperidol on flash and pattern ERGs and VEPs in normal humans. Doc Ophthalmol. 1990;76:55-64.
108. Bartel P, Blom M, Robinson E, Van der Meyden C, Sommers DO, Becker P. Effects of chlorpromazine on pattern and flash ERGs and VEPs compared to oxazepam and to placebo in normal subjects. Electroencephalogr Clin Neurophysiol. 1990;77:330-339.
109. Li X, Dumoulin SO, Mansouri B, Hess RF. Cortical deficits in human amblyopia: their regional distribution and their relationship to the contrast detection deficit. Invest Ophthalmol Vis Sci. 2007;48:1575-1591.
110. Joosse M, Esme DL, Schimsheimer RJ, Verspeek SA, Vermeulen MH, van Minderhout EM. Visual evoked potentials during suppression in exotropic and esotropic strabismics: strabismic suppression objectified. Graefes Arch Clin Exp Ophthalmol. 2005;243:142-150.
111. Basmak H, Yildirim N, Erdinç O, Yurdakul S, Ozdemir G. Effect of levodopa therapy on visual evoked potentials and visual acuity in amblyopia [article in German]. Ophthalmologica. 1999;213:110-113.
112. Sabelli HC, Mosnaim AD. Phenylethylamine Hypothesis of affective behavior. Am J Psychiatry. 1974;131:695-699.
113. Sabelli H, Fink P, Fawcett J, Tom C. Sustained antidepressant effect of PEA replacement. J Neuropsychiatry Clin Neurosci. 1996;8:168-171.
114. Sabelli HC, Javaid JI. Phenylethylamine modulation of affect: therapeutic and diagnostic implications. J Neuropsychiatry Clin Neurosci. 1995;7:6-14.
115. Yasar S, Justinova Z, Lee SH, Stefanski R, Goldberg SR, Tanda G. Metabolic transformation plays a primary role in the psychostimulant-like discriminative-stimulus effects of selegiline [(R)-(-)-deprenyl]. J Pharmacol Exp Ther. 2006;317:387-394.
116. Sotnikova TD, Budygin EA, Jones SR, Dykstra LA, Caron MG, Gainetdinov RR. Dopamine transporter-dependent and-independent actions of trace amine beta-phenylethylamine. J Neurochem. 2004;91:362-373.
117. Brunton L, Chabner B, Knollman B. Goodman & Gilman's Le Basi Farmacologiche Della Terapia, 11th ed. Milan, Italy: McGraw Hill; 2006.
118. Zhou G, Miura Y, Shoji H, Yamada S, Matsuishi T. Platelet monoamine oxidase B and plasma beta-phenylethylamine in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2001;70:229-231.
119. Bergman J, Yasar S, Winger G. Psychomotor stimulant effects of beta-phenylethylamine in monkeys treated with MAO-B inhibitors. Psychopharmacology. 2001;159:21-30.
120. Romay C, Ledón N, González R. Further studies on anti-inflammatory activity of phycocyanin in some animal models of inflammation. Inflamm Res. 1998;47:334-338.
121. Gantar M, Simovic D, Djilas S, Gonzalez WW, Miksovska J. Isolation, characterization and antioxidative activity of C-phycocyanin from Limnothrix sp. strain 37-2-1. J Biotechnol. 2012;159:21-26.
122. Benedetti S, Benedetti Y, Canestrari F, Delgado-Esteban M, Scoglio S. Aphanizomenon flos aquae preparation, extracts and purified components thereof for the treatment of neurological, neurodegenerative and mood disorders. U.S. Patent EP 2046354 B1. August 10, 2011.
123. Rimbau V, Camins A, Romay C, González R, Pallàs M. Protective effects of C-phycocyanin against kainic acid-induced neuronal damage in rat hippocampus. Neurosci Lett. 1999;276:75-78.
124. Secades JJ, Frontera G. CDP-choline: pharmacological and clinical review. Methods Find Exp Clin Pharmacol. 1995;17:1-54.
125. Secades JJ. CDP-choline update and review of its pharmacology and clinical use. Methods Find Exp Clin Pharmacol. 2001;23:1-53.
126. Martínez-Villa E, Sieria PI. Current status and perspectives of neuroprotection in ischemic stroke treatment. Cerebrovasc Dis. 2001;11:60-70.
127. Pecori Giraldi J, Virno M, Covelli G, Grechi G, De Gregorio F. Therapeutic value of citicoline in the treatment of glaucoma (computerized and automated perimetric investigation). Int Ophthalmol. 1989;13:109-112.
128. Parisi V, Manni G, Colacino G, Bucci MG. Cytidine-5'-diphosphocholine (citicoline) improves retinal and cortical responses in patients with glaucoma. Ophthalmology. 1999;106:1126-1134.
129. McMurray WC, Magee WL. Phospholipid metabolism. Annu Rev Biochem. 1972;41:129-161.
130. Hirashima Y, Moto A, Endo S, Takaku A. Activities of enzymes metabolizing phospholipids in rat cerebral ischemia. Mol Chem Neuropathol. 1989;10:87-100.
131. Agut J, Coviella IL, Wurtman RJ. Cytidine(5')diphosphocholine enhances the ability of haloperidol to increase dopamine metabolites in the striatum of the rat and to diminish stereotyped behavior induced by apomorphine. Neuropharmacology. 1984;23:1403-1406.
132. Dávalos A, Castillo J, Alvarez-Sabín J, et al. Oral citicoline in acute ischemic stroke: an individual patient data pooling analysis of clinical trials. Stroke. 2002;33:2850-2857.
133. Fresina M, Dickmann A, Salerni A, De Gregorio F, Campos EC. Effect of oral CDP-choline on visual function in young amblyopic patients. Graefes Arch Clin Exp Ophthalmol. 2008;246:143-150.
134. Campos EC, Bolzani, R, Schiavi C, Baldi A, Porciatti V. Cytidine-5'-diphosphocoline enhances the effect of part-time occlusion in amblyopia. Doc Ophthalmol. 1997;93:247-263.
135. Campos EC, Fresina M. Medical treatment of amblyopia: present state and perspectives. Strabismus. 2006;14:71-73.
136. Mower GD, Christen WG, Burchfiel JL, Duffy FH. Microiontophoretic bicuculline restores binocular responses to visual cortical neurons in strabismic cats. Brain Res. 1984;309:168-172.
137. Burchfiel JL, Duffy FH. Role of intracortical inhibition in deprivation amblyopia: reversal by microiontophoretic bicuculline. Brain Res. 1981;206:479-484.
138. Duffy FH, Burchfiel JL, Mower GD, Joy RM, Snodgrass SR. Comparative pharmacological effects on visual cortical neurons in monocularly deprived cats. Brain Res. 1985;339:257-264.